One in three men will experience moderate to severe lower urinary tract symptoms in their lifetime, with symptoms including ...
LAS VEGAS -- A novel, non-ablative intervention for lower urinary tract symptoms (LUTS) produced rapid, durable symptom relief with no adverse effect on sexual function, long-term results from ...
PORTSMOUTH, N.H., May 8, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a global leader in diagnostic and therapeutic urology, announced the publication of three-year outcomes from ...
PORTSMOUTH, N.H., Jan. 17, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leader in diagnostic and therapeutic medical technologies, has reached a significant milestone with its ...
A postmarketing study showed that the Optilume BPH system improved the flow of urine while leaving sexual function unchanged in men with benign prostatic hyperplasia (BPH), researchers reported at the ...
PORTSMOUTH, N.H., May 13, 2024 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leading diagnostic and therapeutic medical technology company, announced positive 2-year and 5-year ...
A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable improvement in urinary symptoms and flow rate, according to data from three ...
Dr. Austen Slade, in Boise, Idaho, is proud to announce that he is the first urologist in the state to introduce the Optilume® BPH Catheter System. The Optilume technology has been a game changer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results